Connor Clark & Lunn Investment Management Ltd. Has $1.09 Million Position in Meridian Bioscience, Inc. (VIVO)

Connor Clark & Lunn Investment Management Ltd. raised its stake in Meridian Bioscience, Inc. (NASDAQ:VIVO) by 52.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 68,325 shares of the company’s stock after acquiring an additional 23,425 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Meridian Bioscience were worth $1,086,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in VIVO. SG Americas Securities LLC bought a new stake in Meridian Bioscience in the 1st quarter valued at $104,000. Jane Street Group LLC bought a new stake in Meridian Bioscience in the 4th quarter valued at $140,000. Piedmont Investment Advisors LLC bought a new stake in Meridian Bioscience in the 2nd quarter valued at $157,000. Cubist Systematic Strategies LLC bought a new stake in Meridian Bioscience in the 1st quarter valued at $187,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in Meridian Bioscience in the 1st quarter valued at $222,000. Institutional investors own 86.85% of the company’s stock.

Shares of NASDAQ VIVO opened at $14.95 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.89 and a current ratio of 5.73. The firm has a market capitalization of $635.93 million, a price-to-earnings ratio of 22.27 and a beta of 0.85. Meridian Bioscience, Inc. has a 52-week low of $13.50 and a 52-week high of $17.10.

Meridian Bioscience (NASDAQ:VIVO) last announced its quarterly earnings results on Tuesday, July 31st. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.17 by $0.01. The company had revenue of $51.74 million for the quarter, compared to the consensus estimate of $52.17 million. Meridian Bioscience had a net margin of 11.49% and a return on equity of 16.97%. Meridian Bioscience’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.16 EPS. equities analysts forecast that Meridian Bioscience, Inc. will post 0.7 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, August 20th. Shareholders of record on Friday, August 10th will be issued a $0.125 dividend. The ex-dividend date is Thursday, August 9th. This represents a $0.50 dividend on an annualized basis and a yield of 3.34%. Meridian Bioscience’s dividend payout ratio is currently 74.63%.

VIVO has been the topic of a number of research reports. BidaskClub downgraded shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Wednesday, August 8th. TheStreet upgraded shares of Meridian Bioscience from a “c+” rating to a “b” rating in a report on Monday, July 2nd. Finally, Zacks Investment Research upgraded shares of Meridian Bioscience from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Tuesday, May 1st.

Meridian Bioscience Profile

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.

Featured Story: Asset Allocation

Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience, Inc. (NASDAQ:VIVO).

Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply